Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 653,466
  • Shares Outstanding, K 29,676
  • Annual Sales, $ 11,700 K
  • Annual Income, $ -66,820 K
  • 60-Month Beta 0.78
  • Price/Sales 59.49
  • Price/Cash Flow N/A
  • Price/Book 2.23
Trade BCYC with:

Options Overview Details

View History
  • Implied Volatility 96.54% ( -13.64%)
  • Historical Volatility 42.48%
  • IV Percentile 75%
  • IV Rank 33.57%
  • IV High 149.69% on 06/21/22
  • IV Low 69.68% on 10/21/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 546
  • Open Int (30-Day) 584

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.98
  • Number of Estimates 9
  • High Estimate -0.79
  • Low Estimate -1.15
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -66.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.49 +2.70%
on 10/06/22
26.50 -16.72%
on 09/07/22
-3.23 (-12.77%)
since 09/06/22
3-Month
18.75 +17.71%
on 07/07/22
29.53 -25.26%
on 08/11/22
+3.55 (+19.17%)
since 07/06/22
52-Week
12.08 +82.70%
on 06/16/22
62.08 -64.45%
on 11/15/21
-19.63 (-47.07%)
since 10/06/21

Most Recent Stories

More News
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 22.07 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 23.32
2nd Resistance Point 22.84
1st Resistance Point 22.45
Last Price 22.07
1st Support Level 21.59
2nd Support Level 21.11
3rd Support Level 20.72

See More

52-Week High 62.08
Fibonacci 61.8% 42.98
Fibonacci 50% 37.08
Fibonacci 38.2% 31.18
Last Price 22.07
52-Week Low 12.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar